"Hemorrhage" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bleeding or escape of blood from a vessel.
| Descriptor ID |
D006470
|
| MeSH Number(s) |
C23.550.414
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hemorrhage".
Below are MeSH descriptors whose meaning is more specific than "Hemorrhage".
This graph shows the total number of publications written about "Hemorrhage" by people in this website by year, and whether "Hemorrhage" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 3 | 4 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 3 | 3 |
| 2016 | 4 | 4 | 8 |
| 2017 | 3 | 3 | 6 |
| 2018 | 5 | 0 | 5 |
| 2019 | 3 | 2 | 5 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 5 | 6 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 8 | 8 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemorrhage" by people in Profiles.
-
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
-
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024 Mar; 30(2):257-266.
-
FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024 Apr; 22(4):990-1000.
-
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462.
-
Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023 07 11; 7(13):3049-3057.
-
RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. 2023 07; 27(13):1790-1796.
-
Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740.
-
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
-
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
-
A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE. Clin Appl Thromb Hemost. 2023 Jan-Dec; 29:10760296231160748.